Titan Pharmaceuticals (NASDAQ:TTNP) executed a service agreement with AppianRx, a specialty healthcare solutions company, to provide a full suite of patient support services related to Titan’s Probuphine implant, a unique six-month maintenance treatment for opioid use disorder (OUD) in eligible patients.
“We believe AppianRx’s comprehensive patient support services utilizing its patent pending technology platform, Cassia, will help optimize patient care by facilitating more efficient interactions among physicians, payers and specialty pharmacies,” Dane Hallberg, Titan’s chief commercial officer, said in a statement.
“We expect the Cassia platform to lead to significant improvements in the automation and streamlining of the product supply chain process by managing elements such as product ordering and payer pre-approval,” he added.
The companies plan to have the system fully operational early in the second quarter of 2019.
Amit Jain, CEO of AppianRx, said that as the Probuphine customer support center, AppianRx will manage benefits verification; prior authorization and appeals; and co-pay and patient assistance programs to better provide patients with access to the treatment they need.
“AppianRx’s ability to leverage advanced automation and AI technologies allows our support staff to stay focused on what is most important – the care of the patient,” he added.
